Tempus AI heads into its July 30 earnings print with a sharp divergence in its positioning signals — short interest unwinding in one direction, options traders fleeing for cover in the other.
The options market is sending the clearest alarm. The put/call ratio jumped to 0.51 on Tuesday — three standard deviations above its 20-day average of 0.39, the most defensive options read in the past year outside of June's 0.66 peak. That single-day spike follows a week when the ratio spent most of its time near cycle lows. The shift is abrupt and notable: whatever drove the buying pressure that carried TEM through earlier weeks, options traders at least are now paying up for protection with earnings just eight days out. The stock itself has fallen 16.5% on the week to $48.98, a sharp reversal that helps explain the hedging activity.
Short interest tells a more nuanced story. At 18.7% of free float — roughly 32.4 million shares short — the headline level remains elevated, but the direction of travel has been downward. Short positions have declined nearly 3% on the week and are almost 13% below the ~37 million shares that were short at the start of July. That unwind helps explain some of the recovery from the week's lows. Borrowing costs are loose at 0.74%, down about 14% over the past month, and availability is running at 70.5% — considerably more relaxed than June's tightest readings near 12% — meaning there is no shortage of shares to borrow for anyone who wants to press the short. The lending market is not squeezed.
The analyst community is broadly constructive but watching the same cracks. Seven buy ratings and one outperform face a lone Jefferies Underperform with a $35 target — initiated in April — that sits well below the $66.57 consensus mean. Guggenheim raised its target to $65 from $60 last week, a modest upgrade signal. Needham reiterated its $75 buy on Monday, the most recent read. With TEM trading near $49, the consensus implies roughly 36% upside, though the stock has given back nearly all its year-to-date gains. The bull case centres on FDA-approved product momentum, a genomics and data licensing pipeline targeting 25%-plus revenue growth, and deepening pharma partnerships. Bears point to a widening operating loss, customer budget constraints on new logo acquisition, and potential volatility in government-funded programs including the VA's Million Veteran Program.
Institutional flows add colour. ARK Investment Management added over 2 million shares in Q2, bringing its position to 9.6 million shares, or 5.4% of outstanding. BlackRock added 1.45 million shares in the same period, reaching 5.0%. Founder and Chairman/CEO Eric Lefkofsky, the largest holder at 23.2% of shares, sold roughly $3.5 million of stock on June 29 at prices in the mid-to-high $50s. A divisional CEO, Ryan Fukushima, sold a further ~$2.5 million across July 6–8, also in the $56–$60 range. Those sales occurred at prices meaningfully above the current level, a fact the market has likely already absorbed, but the pattern of insider selling into strength is worth noting given the size of Lefkofsky's stake. Net insider activity over the trailing 90 days shows $26 million in net sales.
Looking at the last two quarterly reports for context: the May print saw a modest 2.9% next-day gain, followed by a 9.5% five-day decline. A March event triggered a 4.1% one-day drop and a 15.9% five-day slide. The stock has not rewarded buyers in the days after recent results. The EPS surprise factor score ranks in the 96th percentile — the company has consistently beaten estimates — but consensus momentum has been moving against it, with 30-day and 90-day EPS revisions both sliding. Correlated peers PACB and DNA also had difficult weeks, each falling around 7–13%, suggesting sector-level pressure rather than a TEM-specific story. The July 30 print is therefore less about whether Tempus AI is growing and more about whether management's guidance language on pharma customer engagement and the VA program can stabilise expectations after a punishing month for the stock.
See the live data behind this article on ORTEX.
Open TEM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
